Supplementary Figure 8: Overall survival among lung adenocarcinoma TCGA cases based on inactivating SMARCA4 mutations.
From: Recurrent SMARCA4 mutations in small cell carcinoma of the ovary
Median overall survival was 11.6 months among 6 patients with inactivating SMARCA4 mutations compared with 44.6 months for 197 patients without inactivating mutations.
